Iron is an essential component of heme and hemoglobin. The production of functional erythrocytes therefore requires the timely delivery of sufficient iron to erythroid precursors. The iron supply to the bone marrow comes under particular strain after hemorrhage, hemolysis and other conditions that trigger stress erythropoiesis. Both the absorption of dietary iron and the release of iron from stores are increased as erythropoiesis intensifies, but the mechanism through which erythropoiesis modulates iron homeostasis, historically referred to as the 'erythroid regulator' , is not understood 1 . After loss of erythrocytes through hemorrhage or hemolysis, critical signals facilitating the provision of iron for restorative erythropoiesis would be expected to act within hours, as rapid recovery of red blood cell mass and oxygen-carrying capacity confers obvious evolutionary advantages.
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The liver-produced hormone hepcidin is the main circulating regulator of iron absorption and distribution across tissues 2 . Hepcidin controls the major flows of iron into plasma: absorption of dietary iron in the intestine, recycling of iron by macrophages, which phagocytose old erythrocytes and other cells, and mobilization of stored iron from hepatocytes. Iron is exported from these tissues into plasma through ferroportin, the sole known cellular iron exporter, and the hepcidin receptor. Hepcidin causes endocytosis and degradation of ferroportin, leading to the retention of iron in iron-exporting cells and decreased flow of iron into plasma. In turn, hepcidin production is transcriptionally regulated in response to changes in circulating iron concentrations, iron stores or the development of inflammation and iron-restricted erythropoiesis 2 .
In view of the central role of hepcidin in systemic iron homeostasis, putative erythroid regulators could facilitate iron delivery to the bone marrow by decreasing blood hepcidin levels, thereby allowing increased iron absorption and the release of iron from stores into blood plasma. Indeed, anemia induced by hemorrhage or hemolysis resulted in decreased hepcidin levels in mice 3 , and the suppressive effect of anemia on hepcidin levels was dependent on erythropoietin and functional bone marrow 4, 5 . In normal volunteers, the administration of erythropoietin was sufficient to profoundly lower serum hepcidin levels in less than a day in the absence of any appreciable changes in serum iron concentrations 6 .
In contrast to their adaptive role in recovery from blood loss, erythroid regulators may act pathologically to mediate iron overload and its severe clinical complications in inherited anemias with ineffective erythropoiesis, such as β-thalassemia and congenital dyserythropoietic anemia. This mechanism may be particularly prominent in untransfused individuals in whom iron overload develops because of the pathological suppression of hepcidin synthesis and the resulting hyperabsorption of dietary iron 7 . Even in transfused individuals, in whom ineffective erythropoietic activity is partially ameliorated, erythroid regulators and associated hepcidin suppression might contribute to iron overload, particularly late in the intervals between transfusions. Growth differentiation factor 15 (GDF15) and twisted-gastrulation 1 (TWSG1) are bone morphogenetic protein (BMP) family members that have been proposed to be pathological suppressors of hepcidin levels in thalassemia 8, 9 . However, the evidence for the pathogenic role of these mediators in iron-loading anemias is not definitive, and recent studies argue against their contribution in physiological hepcidin suppression after hemorrhage [10] [11] [12] . Here we describe the identification of a new erythroid regulator essential for the early suppression of hepcidin levels after erythropoietic stimulation.
RESULTS

Suppression of hepcidin by erythropoietic stimulation
We first examined the time course of the hepatic hepcidin response to increased erythropoietic activity. Six-week-old C57BL/6 male mice Identification of erythroferrone as an erythroid regulator of iron metabolism were phlebotomized (volume of blood drawn was 500 µl) or treated with 200 units of human erythropoietin (EPO). Hepcidin (Hamp) mRNA levels were reduced within 9 h of erythropoietic stimulation, reached a nadir of about 10% of baseline 15 h after phlebotomy or EPO treatment, and remained partially decreased even after 48 h (Fig. 1a) . Serum hepcidin concentrations were concordant with the mRNA data (Fig. 1b) . Suppression occurred with similar timing in mice as had been reported in human volunteers (between 9-24 h after EPO injection) 6 ; thus, we focused on the early mechanism of hepcidin suppression, active in the first 24 h after hemorrhage. As was the case in the human study, no significant (P < 0.05) changes in serum iron concentration were observed after either stimulus (Supplementary Fig. 1 ).
The BMP-SMAD signaling pathway is a major regulator of hepcidin transcription 13, 14 and is involved in iron-dependent modulation of hepcidin expression. To assess whether hepatic BMP-SMAD signaling was decreased in response to erythropoietic stimulation, we measured SMAD5 phosphorylation in the livers of phlebotomized or EPO-treated mice 15 h after stimulus. SMAD5 phosphorylation was not significantly decreased in either phlebotomized ( Supplementary Fig. 2a,b) or EPOtreated ( Supplementary Fig. 2c,d ) mice compared to control mice. We also examined Id1 mRNA levels, which are a well-established marker of BMP-SMAD activation 15 . In contrast to the profound suppression of hepcidin levels observed, only a mild decrease in Id1 mRNA levels was observed 9 and 15 h after phlebotomy, and no changes were observed 12 h after bleeding or at any time point after EPO treatment (Supplementary Fig. 2e ). Together, these data suggest that hepcidin suppression by increased erythropoietic activity occurs independently of the canonical BMP-SMAD signaling pathway. Moreover, using mice deficient in transferrin receptor 2 (Tfr2 Y245X/Y245X ) or hemojuvelin (Hfe2 -/-), important regulators of the hepcidin response to iron and modulators of BMP signaling, we showed that neither TfR2 or HJV was required for erythropoietic suppression of hepcidin ( Supplementary  Fig. 3a,b) . Additionally, we stimulated the BMP pathway in wildtype mice by parenterally administering iron to cause extreme iron overload (liver iron content is shown in Supplementary Fig. 3c ). Even in these mice with very high baseline levels of hepcidin, phlebotomy acutely suppressed hepcidin levels (Supplementary Fig. 3b) . Thus, the erythropoietic suppression of hepcidin appears to act independently of the BMP pathway.
Bone marrow gene expression profiling
Guided by previous studies 4, 5 suggesting that the erythroid regulator might be secreted by the bone marrow after erythropoietic stimulation, we studied mRNA changes in mouse bone marrow 0-48 h after bleeding using Affymetrix gene chip-based expression profiling. No changes were observed in the mRNA levels of Gdf15 and Twsg1, which encode previously proposed candidates for the erythroid regulator. We focused our attention on erythroid-specific transcripts encoding secreted proteins whose mRNA levels were induced before and maintained at high levels during the suppression of hepatic hepcidin mRNA levels. A previously uncharacterized transcript, listed in the databases as Fam132b, fit these criteria: it was predicted to encode a secreted protein and was highly induced within 4 h of bleeding, before hepcidin suppression. After its further characterization, we named this factor 'erythroferrone' (ERFE) to denote its function as an erythroid hormone acting on iron metabolism. In the meantime, the protein encoded by Fam132b was also described by others 16 as myonectin or CTRP15, a member of the C1q/tumors necrosis factor (TNF)-related protein family (CTRP). Pending definitive resolution of the nomenclature, we will refer to erythroferrone protein as ERFE and to the corresponding mRNA and gene as Fam132b.
Validation studies using quantitative RT-PCR (qRT-PCR) demonstrated that Fam132b mRNA levels were already induced in the bone marrow within 4 h of phlebotomy and reached maximal induction with an over 30-fold increase by 9 h (Fig. 2a) , before decreasing toward baseline levels after 24-48 h. Fam132b mRNA expression after phlebotomy mirrored serum EPO concentrations ( Supplementary  Fig. 4 ). EPO treatment resulted in a similar (but more rapid) induction of Fam132b mRNA levels, suggesting that the gene encoding ERFE is EPO responsive (Fig. 2a) . In the absence of any stimulation, Fam132b mRNA in the spleen was expressed at very low levels, but its expression was increased by eight-to tenfold after phlebotomy or EPO injection (Fig. 2b) , supporting its role in stress erythropoiesis. The induction of Fam132b mRNA levels by phlebotomy was not affected by modulation of BMP signaling through iron loading or genetic ablation of Tfr2 or hemojuvelin (Hfe2) (Supplementary Fig. 3d ).
ERFE is produced by erythroblasts
We next assessed the tissue-specific expression of Fam132b mRNA in control and EPO-treated 6-week-old male wild-type mice. At baseline, the highest Fam132b expression was detected in colon, duodenum, muscle, bone marrow and testis (Fig. 3a) . After EPO stimulation, however, induction of Fam132b levels was observed only in bone were compared to the levels in control mice at t = 0 by two-tailed Student's t test (n = 4 mice per time point and condition). ***P < 0.001, **P < 0.01, *P < 0.05 for phlebotomy; ### P < 0.001, ## P < 0.01, # P < 0.05 for EPO treatment. to values for control mice at t = 0 by two-tailed Student's t test (n = 4 mice per group and condition). ***P < 0.001, **P < 0.01, *P < 0.05 for phlebotomy; ### P < 0.001, ## P < 0.01, # P < 0.05 for EPO treatment. VOLUME 46 | NUMBER 7 | JULY 2014 Nature GeNetics A r t i c l e s marrow and spleen, the erythropoietic organs of the adult mouse. Moreover, EPO-stimulated bone marrow became the organ with the highest expression of Fam132b mRNA, supporting the idea that this factor might have erythroid-specific function. To examine Fam132b expression across the stages of erythroid differentiation, we used flow cytometry to sort erythroblast populations derived from the bone marrow of control, wild-type mice and phlebotomized wild-type mice (15-h time point). Erythroblast populations were separated on the basis of cell size and expression of the erythroid markers TER119 and transferrin receptor 1 (TFR1) into proerythroblasts and basophilic, polychromatic and orthochromatic erythroblasts, as previously described 17 . Fam132b mRNA levels were higher after phlebotomy in all four populations of erythroid precursors, with the highest expression detected in basophilic and polychromatic erythroblasts (Fig. 3b) . The cDNA sequence available for human FAM132B in public databases (GenBank, XM_001714385.4) had been predicted from the genomic sequence and was not validated by mRNA sequencing. We performed 5′ RACE on total RNA from human fetal liver erythroblasts and cloned the dominant cDNA sequence, which differed from the predicted sequence at the 5′ end, including the codons for the first 70 amino acids. taking into account this change, the human and mouse ERFE protein sequences contain 354 and 340 amino acids, respectively, and are 71% identical. The C-terminal halves of the predicted proteins have even higher identity and encode a TNF-α-like domain 16 . In human erythroblasts isolated from fetal liver or adult bone marrow, FAM132B mRNA expression was also strongly induced by EPO (>16-fold increase in mRNA levels) (Supplementary Fig. 5 ).
Binding of EPO to its receptor is known to activate the JAK2-STAT5 signaling pathway that is necessary for stress erythropoiesis 18 . Because in silico analysis of the mouse Fam132b promoter spanning 3,000 bp upstream of the transcription initiation site identified multiple putative STAT5 binding elements (MatInspector, Genomatix Software) (Supplementary Table 1) , we explored the involvement of this pathway in ERFE regulation. Treatment of total mouse bone marrow cells with two chemically unrelated STAT5 inhibitors (pimozide or N′-((4-oxo-4H-chromen-3-yl)methylene)nicotinohydrazide) before a 15-h incubation with EPO inhibited Fam132b mRNA stimulation (Fig. 3c) . Thus, EPO regulates Fam132b expression in erythroblasts through the stress erythropoiesis-related JAK2-STAT5 signaling pathway.
In contrast, we found no effect of hypoxia-related or systemic inflammatory signaling on Fam132b mRNA expression in the bone marrow. Treatment of mouse bone marrow cells in vitro with dimethyloxalylglycine (DMOG), an inhibitor of the oxygen-sensing prolyl hydroxylases that mediate hypoxia-related signaling, had no effect on Fam132b mRNA levels, even though it strongly induced Vegfa mRNA levels (Supplementary Fig. 6 ). Fam132b mRNA concentrations in bone marrow were also unresponsive to acute inflammatory stimulus in vivo. Four hours after injection of lipopolysaccharide (LPS) into mice, TNF-α (Tnfa), interleukin (IL)-6 (Il6) and hepcidin (Hamp1) mRNA levels were increased, but Fam132b mRNA expression was unchanged (Supplementary Fig. 7 ).
ERFE-deficient mice have a transient hemoglobin deficit
Fam132b −/− mice were previously generated as part of a large-scale mouse knockout library 19 and were reported to be viable and fertile without any abnormal phenotypic features. In our more detailed . Expression ratios ± s.e.m. for Fam132b transcripts in EPO-treated cells relative to controls normalized to mRNA levels for the Gypa gene were calculated using REST (Relative Expression Software Tool). Normalization by Gypa levels allowed normalization of Fam132b mRNA levels by red blood cell. Results of three independent experiments with 15 h of treatment in duplicate are shown. Statistical significance was determined using randomization tests. ***P < 0.001, **P < 0.01. (Fig. 4a,b) , a time of rapid growth, erythropoietic expansion and high demand for iron. Six-week-old Fam132b +/− heterozygotes also exhibited slightly decreased hemoglobin levels compared to wild-type mice (Supplementary Fig. 8a ). In contrast, Fam132b −/− mice at 3, 12 and 24 weeks had hematological parameters similar to those of wild-type mice. Fam132b −/− mice exhibited a trend toward lower mean corpuscular volume (MCV) at 6, 12 and 24 weeks and toward lower serum iron concentrations at 6 weeks, but differences were not statistically significant (Supplementary Fig. 9 ).
We did not observe any baseline difference in liver iron or hepcidin concentrations among Fam132b +/+ , Fam132b +/− and Fam132b −/− littermates at the ages they were examined (3, 6 and 24 weeks) ( Supplementary Figs. 8 and 10) . Spleen iron content was measured at 6 weeks of age and was also similar in wild-type and Fam132b −/− mice (Supplementary Fig. 8d ).
ERFE is required for hepcidin suppression after blood loss
To determine whether ERFE is an erythroid regulator necessary for hepcidin regulation by increased erythropoietic activity, we studied the hepatic hepcidin response to phlebotomy in 6-week-old Fam132b +/+ , Fam132b +/− and Fam132b −/− littermate mice. In contrast to the rapid and profound suppression of hepcidin mRNA levels seen in Fam132b +/+ mice (suppression to 10% at 15 h after phlebotomy), Fam132b-deficient mice failed to mount this response (Fig. 5a) . Even Fam132b +/− mice showed blunted suppression of hepcidin (to ~25%) compared to their wild-type counterparts, consistent with lower levels of Fam132b mRNA expression in the bone marrow (Fig. 5b) . After phlebotomy, serum iron concentrations in Fam132b −/− mice (but not in Fam132b +/+ mice) were significantly lower than at baseline at all time points examined, consistent with lack of suppression of hepcidin and a homeostatic defect in iron regulation after hemorrhage (Supplementary Fig. 11 ). These results support our hypothesis that ERFE is required for the regulation of hepcidin levels by increased erythropoietic demand. Flow cytometry analysis of bone marrow Fam132b-deficient mice showed delayed recovery of hemoglobin (c) and lower MCH levels (d) than wild-type mice. In c,d, hematological parameters were compared for each measurement in wild-type (n = 17) and knockout (n = 15) mice by Student's t test. All graphs show means ± s.e.m. In the absence of differences between the sexes, data for both sexes were combined for each parameter. ***P < 0.001, **P < 0.01, *P < 0.05. Six male C57BL/6 mice were injected intraperitoneally with either recombinant mouse ERFE (2 µg/g body weight) or saline solution and analyzed 15 h later. Hepatic hepcidin mRNA (a) and serum hepcidin (b) levels were significantly suppressed by ERFE treatment. (c-e) Seven-week-old male C57BL/6 mice were transduced with a lentivirus encoding GFP or mouse ERFE (n = 8 mice per group) and analyzed after 3 weeks. (c) Fam132b mRNA was not detectable (ND) in the liver of control mice, and levels were moderately higher in the liver of mice transduced with the ERFE-encoding lentivirus, although they were only twofold higher than the baseline levels in bone marrow. However, this increase was sufficient to significantly reduce hepatic hepcidin mRNA (d) and serum hepcidin (e) levels. Fig. 12 ), suggesting that ERFE is not necessary for erythroblast differentiation at baseline and during stress erythropoiesis. We next investigated whether ERFE facilitated compensatory iron acquisition during recovery from hemorrhage. Twelve-week-old Fam132b +/+ and Fam132b −/− mice were phlebotomized, and their hematological parameters were monitored for 9 d. Throughout this period, ERFE-deficient mice exhibited lower hemoglobin concentrations, MCH levels, MCV and hematocrit levels than wild-type controls (Fig. 5c,d and Supplementary Fig. 13) , demonstrating that the recovery of ERFE-deficient mice from hemorrhage-induced anemia was delayed by several days.
ERFE acts on the liver to suppress hepcidin
To test whether secreted ERFE protein is a suppressor of hepcidin, we injected male C57BL/6 mice with recombinant mouse ERFE (2 µg/g body weight). We found that hepcidin mRNA and serum protein levels were significantly reduced 15 h after ERFE treatment compared to in saline-injected mice (Fig. 6a,b) , despite a substantial inflammatory response (as shown by increased expression of Saa1 mRNA; Supplementary Fig. 14a ), which would be expected to increase hepcidin levels. Using high-performance gel-permeation chromatography under nondenaturing conditions, we confirmed a previous report 16 that the purified recombinant protein had an effective molecular mass of 500-600 kDa, suggesting that it was highly aggregated, a tendency shared by several other members of the TNF-α superfamily. Measures that decrease aggregation might decrease the inflammatory effects of the recombinant protein and further increase its potency.
To avoid the acute inflammatory effect of the recombinant ERFE preparation, we administered male C57BL/6 mice a lentivirus-based vector encoding ERFE or a control vector (expressing GFP). Three weeks later, although we only achieved a modest increase in Fam132b mRNA levels in the liver (but not in the bone marrow) (Fig. 6c) , hepcidin mRNA and serum protein levels were reduced to 3% and 10%, respectively (Fig. 6d,e) , suggesting that even a small amount of ERFE in the liver was sufficient to exert its inhibitory effect on hepcidin transcription. Saa1 mRNA levels were not increased in these mice (Supplementary Fig. 14b ). Neither injection with recombinant ERFE or chronic lentiviral expression of ERFE affected the BMP pathway, as measured by the expression of its canonical target, Id1 (Supplementary Fig. 14c,d) . We then tested whether ERFE could act directly on the liver to regulate hepcidin levels. To circumvent the aggregation of recombinant ERFE and loss of potency during the purification process, we treated mouse primary hepatocytes for 15 h with 50% supernatants in growth medium from control HEK293T cells or HEK293T cells overexpressing ERFE (Fig. 6f) , resulting in a decrease to 25% in hepcidin mRNA levels in ERFE-treated cells (Fig. 6g) . Taken together, these results show that ERFE is a potent suppressor of hepcidin that can act directly on the liver to repress hepcidin mRNA expression.
Mice with -thalassemia intermedia have high levels of ERFE
Hbb th3/+ mice are an established model of β-thalassemia intermedia and exhibit anemia, ineffective erythropoiesis and splenomegaly 20 . Their hepatic hepcidin expression is inappropriately low, leading to hyperabsorption of iron and hepatic iron overload 20 . We assayed Fam132b mRNA levels in bone marrow and spleen from 6-weekold Hbb th3/+ mice. As expected, the mice were anemic and had very high serum EPO concentrations (Fig. 7a,b) . Compared to their wildtype littermates, Hbb th3/+ mice had Fam132b mRNA levels that were increased by 10-fold in the bone marrow and by 16-fold in the spleen (Fig. 7c) , suggesting that ERFE may be involved in hepcidin dysregulation in β-thalassemia. Ablation of ERFE in β-thalassemic mice (Fam132b −/− ; Hbb th3/+ ) resulted in higher hepcidin levels (Fig. 7d) and less hepatic iron overload (Fig. 7e) than in Hbb th3/+ mice. Figure 8 Proposed role of the erythroid factor erythroferrone (ERFE). After erythropoietic stimulation, differentiating erythroblasts in the bone marrow and spleen rapidly increase ERFE production in an EPO-and STAT5-dependent manner. ERFE is secreted into the circulation and acts directly on the liver to repress hepcidin production. ERFE-mediated hepcidin suppression in turn increases iron availability for new red blood cell synthesis.
Consistent with the expected effect of increased hepcidin levels in Fam132b −/− ; Hbb th3/+ mice, serum iron concentrations and erythrocyte MCV and MCH levels were also decreased compared to in Hbb th3/+ mice (Supplementary Fig. 15 ). Thus, ERFE contributes to hepcidin suppression and iron overload in this model of β-thalassemia intermedia.
DISCUSSION
The search for the erythroid regulator of iron homeostasis that assures adequate iron supply for increased erythropoietic activity has been ongoing for many years 1 . Discovery of the iron-regulatory hormone hepcidin and its suppression in anemia suggested a mechanism. It was proposed that hepcidin suppression in anemias might result from direct hepcidin regulation through hepatocellular hypoxia 3, 21 or EPO 3, 22 . However, later studies provided convincing evidence against a biologically important, direct effect of hypoxia on hepcidin transcription 23 . The lack of hepcidin suppression after bleeding or EPO injections in mice with ablated bone marrow 4,5,23 also argues against a direct effect of hypoxia or EPO. Rather, these studies suggest that high levels of EPO cause hepcidin suppression indirectly by inducing the secretion of erythroid regulators from the bone marrow, which in turn act on the liver to suppress hepcidin expression and increase iron delivery from dietary absorption and stores. We therefore initiated a search, using a gene expression microarray, for a potential hepcidin suppressor whose expression was highly induced in the bone marrow before hepcidin suppression in the liver (Fig. 1) . We focused on secreted proteins whose mRNA expression was rapidly increased 4 h after phlebotomy or EPO injection and identified the orphan TNF-α superfamily member encoded by Fam132b as a new erythroid regulator secreted by differentiating erythroblasts (Figs. 2 and 3) . We named this factor erythroferrone, as our results suggest that it functions as a hormone linking erythropoiesis and iron metabolism (Fig. 8) . In human gene expression databases, FAM132B was highly expressed in bone marrow and fetal liver, and an in vitro study of differentiated human erythroblasts 24 reported that FAM132B expression was highest in intermediate erythroblasts. We documented high expression of Fam132b and FAM132B mRNA in mouse and human erythroblasts and established that this expression is greatly induced by erythropoietic stimulation ( Fig. 3 and Supplementary Fig. 5 ) but is not directly affected by hypoxia-related or inflammatory stimuli ( Supplementary  Figs. 6 and 7) . In the meantime, another study reported that mouse FAM132B (also termed myonectin or CTRP15) is generated predominantly in skeletal muscle, has expression that is suppressed by fasting and induced by refeeding, and participates in the regulation of systemic lipid metabolism 16 . That study, however, did not include an analysis of bone marrow. Further work will be needed to understand how these distinct activities coexist and to assess their respective biological and pathological relevance.
In the absence of ERFE, the mechanism suppressing hepcidin early after erythropoietic stimulation is abrogated, and Fam132b-deficient mice exhibit a delay of several days in recovery from hemorrhage compared to wild-type mice (Fig. 5) . This finding confirms that ERFE is a physiological regulator of hepcidin expression and is required for the rapid compensatory response to hemorrhage. Nevertheless, Fam132b-deficient mice do recover from hemorrhage, suggesting that other mechanisms eventually increase iron availability for the synthesis of new erythrocytes. This is not surprising, as recovery from hemorrhage is subject to strong evolutionary pressure and is likely mediated by multiple mechanisms. Even if hepcidin expression is not rapidly suppressed, increased iron demand from accelerated erythropoiesis could eventually cause transient iron deficiency (decreased plasma iron concentration), which would be expected to decrease hepcidin levels and therefore increase iron absorption and release from stores. Interestingly, mature Fam132b-deficient mice at baseline do not exhibit any detectable abnormalities, as their iron parameters and hepcidin expression levels are similar to those of wild-type controls (Supplementary Figs. 8-10 and 12) . Moreover, the induction of Fam132b mRNA levels after blood loss was not modulated by the BMP-SMAD pathway or iron (Supplementary Fig. 3d) . Thus, ERFE is a stress erythropoiesis-specific regulator and does not have a major role in baseline erythropoiesis. Consistent with this idea, ERFE ablation in mice only causes a transient deficit in hemoglobin synthesis as erythropoiesis intensifies during rapid growth between 3 and 6 weeks of age (Fig. 4) . The strong dependence of the induction of Fam132b expression by EPO on the STAT5 pathway (Fig. 3c) is also consistent with a role for ERFE in stress erythropoiesis.
In mice, injection of recombinant ERFE or ERFE overexpression using lentiviral vectors confirmed that ERFE is an effective suppressor of hepcidin in vivo (Fig. 6) . Treatment of primary hepatocytes with ERFE demonstrated that the hormone exerts its hepcidin-suppressive activity directly on hepatocytes (Fig. 6g) . Further work is needed to identify the receptor(s) of ERFE and the downstream effectors controlling hepcidin expression. The BMP-SMAD signaling pathway, the principal pathway mediating iron-dependent regulation of hepcidin, might not be involved in ERFE-mediated hepcidin regulation as neither HJV or TfR2 was necessary for rapid hepcidin suppression after blood loss (Supplementary Fig. 3 ), SMAD5 phosphorylation was not decreased (Supplementary Fig. 2a-d) and levels of Id1, a canonical target of the BMP pathway, were not appreciably affected by erythropoietic stimulation (Supplementary Fig. 2e ) or ERFE treatment (Supplementary Fig. 14) . Thus, although both the iron-regulated BMP-SMAD pathway and the EPO-regulated ERFE pathway converge on hepcidin, we did not find evidence of cross-talk between them. Suppression of hepcidin mRNA levels mediated by hemorrhage and ERFE was observed over a large range of iron loads and baseline hepcidin mRNA concentrations, and the ERFE signal appeared to act on the hepcidin gene independently of the iron-regulated BMP-SMAD pathway. A recent study of hepcidin regulation by iron in an EPO-overproducing mouse model 25 also supports the existence of independent pathways regulating hepcidin in response to hepatic iron load and erythropoietic activity.
Hepcidin suppression by increased erythropoietic activity underlies the development of iron overload in inherited anemias with ineffective erythropoiesis. Such a phenotype is particularly evident in untransfused humans 26, 27 , in whom hyperabsorption of dietary iron is the sole source of iron overload. Studies of human subjects will be necessary to establish whether ERFE has a role in hepcidin suppression and iron overload in anemias with ineffective erythropoiesis. The production of ERFE would be expected to increase in iron-loading anemias with ineffective erythropoiesis, considering that affected individuals have high EPO levels and massively expanded erythroblast populations 28 . Indeed, our measurements in the mouse model of β-thalassemia intermedia (Fig. 7c) document a large increase in Fam132b mRNA expression in the bone marrow and spleen. Ablation of Fam132b in a mouse model of β-thalassemia intermedia reverses the hepcidin defect and decreases hepatic iron overload (Fig. 7d,e) , serum iron concentrations and erythrocyte MCV and MCH levels (Supplementary Fig. 15 ). Thus, ERFE is a strong candidate for a pathological hepcidin suppressor in inherited anemias with ineffective erythropoiesis, in which hepcidin levels are inversely correlated with EPO concentrations and erythropoietic activity 29, 30 . Although the changes induced by ERFE ablation are smaller and do not affect blood hemoglobin concentrations, the pattern is otherwise similar to the effect of pharmacologically induced increases in hepcidin expression in β-thalassemic mice [31] [32] [33] . If the contribution of ERFE to hepcidin suppression and iron overload in iron-loading anemias is confirmed in clinical studies, ERFE neutralization would be a rational and apparently specific therapeutic strategy. At the other end of the disease spectrum, the ability of ERFE to suppress hepcidin expression could be useful in treating iron-restrictive anemias characterized by increased hepcidin, including anemia of inflammation, anemia of chronic kidney diseases and iron-refractory irondeficiency anemia 34 .
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